GPN Vaccines Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
36
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$13.5M
- Investors
-
7
GPN Vaccines General Information
Description
Developer of serotype-independent bacterial vaccines designed to provide broad protection against pathogens. The company offers a pneumococcal vaccine, a bacterial vaccine, a veterinary vaccine, a clinical-stage candidate, a whole-cell vaccine, and a serotype-independent vaccine, enabling healthcare providers to achieve immunity against all bacterial strains with a single vaccine.
Contact Information
Website
www.gpnvaccines.comCorporate Office
- C/o Meister Seelig & Fein, PLLC
- 125 Park Avenue, 7th Floor
- New York, NY 10017
- United States
Corporate Office
- C/o Meister Seelig & Fein, PLLC
- 125 Park Avenue, 7th Floor
- New York, NY 10017
- United States
GPN Vaccines Timeline
GPN Vaccines Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 03-Nov-2026 | $13.5M | Completed | Clinical Trials - General | ||
| 8. Later Stage VC (Series B2) | Cancelled | Clinical Trials - General | ||||
| 7. Later Stage VC (Series B1) | 06-Jun-2024 | Completed | Clinical Trials - General | |||
| 6. Accelerator/Incubator | 07-May-2024 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC (Series A3) | 31-Jan-2023 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series A2) | 30-Jun-2020 | Completed | Clinical Trials - General | |||
| 3. Grant | 11-Apr-2020 | Completed | Clinical Trials - General | |||
| 2. Seed Round | 28-Feb-2018 | $333K | $333K | Completed | Pre-Clinical Trials | |
| 1. Grant | 01-Jan-2018 | $300K | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
GPN Vaccines Patents
GPN Vaccines Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023901596-A0 | Immunogenic composition | Pending | 22-May-2023 | ||
| EP-4731253-A1 | Modified streptococcal immunogen and uses thereof | Pending | 22-May-2023 | ||
| US-20260335422-A1 | Modified streptococcal immunogen and uses thereof | Pending | 22-May-2023 | ||
| WO-2024239063-A1 | Modified streptococcal immunogen and uses thereof | Inactive | 22-May-2023 | ||
| JP-2022179236-A | Streptococcal vaccine formulations and uses thereof | Pending | 22-May-2020 | A61K39/092 |
GPN Vaccines Signals
GPN Vaccines Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Kern Capital | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Brandon Biocatalyst | Venture Capital | Minority | ||
| Southern Angels | Angel Group | Minority | ||
| Forepont Capital Partners | Venture Capital | Minority |
GPN Vaccines Acquisitions (1)
GPN Vaccines’s most recent deal was a Merger/Acquisition with BacVax. The deal was made on 27-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BacVax | 27-Oct-2025 | Merger/Acquisition | Drug Discovery |
GPN Vaccines Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| BacVax | Phoenix, AZ | 2021 |
GPN Vaccines FAQs
-
When was GPN Vaccines founded?
GPN Vaccines was founded in 2017.
-
Where is GPN Vaccines headquartered?
GPN Vaccines is headquartered in New York, NY.
-
What is the size of GPN Vaccines?
GPN Vaccines has 36 total employees.
-
What industry is GPN Vaccines in?
GPN Vaccines’s primary industry is Drug Discovery.
-
Is GPN Vaccines a private or public company?
GPN Vaccines is a Private company.
-
What is GPN Vaccines’s current revenue?
The current revenue for GPN Vaccines is .
-
How much funding has GPN Vaccines raised over time?
GPN Vaccines has raised $37.7M.
-
Who are GPN Vaccines’s investors?
Kern Capital, , Brandon Biocatalyst, Southern Angels, and Forepont Capital Partners are 5 of 7 investors who have invested in GPN Vaccines.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process